2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

2019 ASCCP Risk-Based Management Consensus Guidelines Committee

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
JournalJournal of Lower Genital Tract Disease
Issue number1
StatePublished - Jan 1 2024


  • 2019 ASCCP guidelines
  • cervical cancer screening and management
  • updates

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of '2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023'. Together they form a unique fingerprint.

Cite this